WKEY
WISeKey International Holding AG
Semiconductors
Market Cap$26M
5Y Perf.-64.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
WKEY vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-50.2%
WKEY vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | WKEY | XTLB |
|---|---|---|
| Industry | Semiconductors | Biotechnology |
| Market Cap | $26M | $294K |
| Revenue (TTM) | $33M | $451K |
| Net Income (TTM) | $-36M | $-1M |
| Gross Margin | 53.5% | 26.4% |
| Operating Margin | -186.9% | -481.6% |
| Total Debt | $9M | $138K |
| Cash & Equiv. | $91M | $371K |
WKEY vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WKEY
XTLB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| WISeKey Internation… (WKEY) | 100 | 35.2 | -64.8% |
| XTL Biopharmaceutic… (XTLB) | 100 | 49.8 | -50.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WKEY vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: WKEY leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
WKEY
WISeKey International Holding AG
The Growth Leader
WKEY carries the broadest edge in this set and is the clearest fit for growth and quality.
- -61.6% revenue growth vs XTLB's -173.2%
- -108.7% margin vs XTLB's -227.7%
- +87.2% vs XTLB's -50.9%
Best for: growth and quality
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.71
- EPS growth 45.5%
- -87.3% 10Y total return vs WKEY's -91.8%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | WKEY | -61.6% revenue growth vs XTLB's -173.2% |
| Quality / Margins | WKEY | -108.7% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs WKEY's 3.64, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | WKEY | +87.2% vs XTLB's -50.9% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs WKEY's -23.1%, ROIC -54.1% vs -195.8% |
WKEY vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
WKEY vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLWKEYLAGGINGXTLB
XTLBXTL Biopharmaceutical…
2leads
WKEYWISeKey International…
2leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
WKEY5/5
Valuation MetricsMultiples, price ratios, and targets
XTLB2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
WKEY4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
WKEY leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
WKEY is the larger business by revenue, generating $33M annually — 73.1x XTLB's $451,000. Profitability is closely matched — net margins range from -108.7% (WKEY) to -2.3% (XTLB).
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $33M | $451,000 |
| EBITDAEarnings before interest/tax | -$60M | -$1M |
| Net IncomeAfter-tax profit | -$36M | -$1M |
| Free Cash FlowCash after capex | -$41M | $0 |
| Gross MarginGross profit ÷ Revenue | +53.5% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -186.9% | -4.8% |
| Net MarginNet income ÷ Revenue | -108.7% | -2.3% |
| FCF MarginFCF ÷ Revenue | -123.2% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +45.4% | +20.0% |
WKEY leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
XTLB leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $26M | $293,767 |
| Enterprise ValueMkt cap + debt − cash | -$55M | $60,767 |
| Trailing P/EPrice ÷ TTM EPS | -2.99x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.21x | 0.65x |
| Price / BookPrice ÷ Book value/share | 0.45x | 0.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-28 for WKEY. XTLB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to WKEY's 0.10x.
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -28.3% | -25.5% |
| ROA (TTM)Return on assets | -23.1% | -17.7% |
| ROICReturn on invested capital | -195.8% | -54.1% |
| ROCEReturn on capital employed | -44.9% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.10x | 0.03x |
| Net DebtTotal debt minus cash | -$82M | -$233,000 |
| Cash & Equiv.Liquid assets | $91M | $371,000 |
| Total DebtShort + long-term debt | $9M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -16.33x | -13.31x |
XTLB leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
WKEY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WKEY five years ago would be worth $2,023 today (with dividends reinvested), compared to $1,963 for XTLB. Over the past 12 months, WKEY leads with a +87.2% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors WKEY at 11.7% vs XTLB's -18.4% — a key indicator of consistent wealth creation.
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -8.4% | +11.3% |
| 1-Year ReturnPast 12 months | +87.2% | -50.9% |
| 3-Year ReturnCumulative with dividends | +39.4% | -45.7% |
| 5-Year ReturnCumulative with dividends | -79.8% | -80.4% |
| 10-Year ReturnCumulative with dividends | -91.8% | -87.3% |
| CAGR (3Y)Annualised 3-year return | +11.7% | -18.4% |
WKEY leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — WKEY and XTLB each lead in 1 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than WKEY's 3.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. WKEY currently trades 40.0% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.64x | 1.71x |
| 52-Week HighHighest price in past year | $19.80 | $10.28 |
| 52-Week LowLowest price in past year | $4.18 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +40.0% | +26.0% |
| RSI (14)Momentum oscillator 0–100 | 63.2 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 102K | 2.4M |
Evenly matched — WKEY and XTLB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | WKEYWISeKey Internati… | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
WKEY leads in 2 of 6 categories (Income & Cash Flow, Total Returns). XTLB leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallWISeKey International Holdi… (WKEY)Leads 2 of 6 categories
Loading custom metrics...
WKEY vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — WKEY or XTLB?
Over the past 5 years, WISeKey International Holding AG (WKEY) delivered a total return of -79.
8%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: XTLB returned -87. 3% versus WKEY's -91. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — WKEY or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus WISeKey International Holding AG's 3. 64β — meaning WKEY is approximately 114% more volatile than XTLB relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 10% for WISeKey International Holding AG — giving it more financial flexibility in a downturn.
03Which has better profit margins — WKEY or XTLB?
WISeKey International Holding AG (WKEY) is the more profitable company, earning -113.
2% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -113. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WKEY leads at -230. 9% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — WKEY leads at 36. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — WKEY or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is WKEY or XTLB better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. WISeKey International Holding AG (WKEY) carries a higher beta of 3. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -87. 3%, WKEY: -91. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between WKEY and XTLB?
These companies operate in different sectors (WKEY (Technology) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.